A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

2025-522543-18-00 Protocol CA242-0001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 25 Mar 2026 · Status Ongoing, recruiting · 2 EU/EEA countries · 3 sites · Protocol CA242-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 125
Countries 2
Sites 3

Advanced Clear Cell Renal Cell Carcinoma

Key facts

Sponsor
Bristol-Myers Squibb Services Unlimited Company
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
25 Mar 2026 → ongoing
Decision date (initial)
2026-02-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-522543-18-00
WHO UTN
U1111-1323-5879
ClinicalTrials.gov
NCT07195682

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Clear Cell Renal Cell Carcinoma

VersionLevelCodeTermSystem organ class
20.1 LLT 10080007 Clear cell renal cell carcinoma metastatic 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bristol-Myers Squibb Services Unlimited Company

Sponsor organisation
Bristol-Myers Squibb Services Unlimited Company
Address
Plaza 254, Blanchardstown Corporate Park 2 Blanchardstown Corporate Park 2
City
Dublin 15
Postcode
D15 T867
Country
Ireland

Scientific contact point

Organisation
Bristol-Myers Squibb Services Unlimited Company
Contact name
GSM-CT

Public contact point

Organisation
Bristol-Myers Squibb Services Unlimited Company
Contact name
GSM-CT

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 16 1
Spain Authorised, recruiting 32 2
Rest of world
Canada, United States
77

Investigational sites

France

1 site · Ongoing, recruiting
Institut Gustave Roussy
Innovation Thérapeutique et Essais Précoces, 114 Rue Edouard Vaillant, 94800, Villejuif

Spain

2 sites · Authorised, recruiting
Hospital Universitario Reina Sofia
Oncologia, Avenida Menendez Pidal S/n, 14004, Cordoba
Hospital Universitari Vall D Hebron
Oncologia-VHIO, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2026-03-25 2026-05-06
Spain 2026-04-15

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-13 France Acceptable
2026-02-04
2026-02-09